New drug combo tested for Tough-to-Treat breast cancer
NCT ID NCT04762979
Summary
This study is testing whether adding the drug alpelisib to standard hormone therapy can help control advanced breast cancer that has a specific genetic change (PIK3CA mutation) and has stopped responding to hormone therapy alone. It will involve about 44 adults with this type of breast cancer that has spread. The main goal is to see if this combination can delay the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.